Literature DB >> 12112541

Differentiated thyroid carcinoma: comparison between papillary and follicular carcinoma in a single institute.

Sin-Ming Chow1, Stephen C K Law, Siu-Kie Au, To-Wai Leung, Paddy T M Chan, William M Mendenhall, Wai-Hon Lau.   

Abstract

PURPOSE: To compare and contrast the clinical presentation and treatment outcome of patients with papillary and follicular thyroid carcinoma and to study the pattern of practice of treatment of differentiated thyroid carcinoma in Hong Kong.
METHOD: The clinical presentation and treatment outcomes were reviewed for 1057 patients with differentiated thyroid cancers who were treated at the Queen Elizabeth Hospital, Hong Kong, from 1960 to 1997. Eight hundred forty-two patients had papillary thyroid carcinomas (PTC), and 215 had follicular thyroid carcinomas (FTC). The mean follow-up was 9.2 years.
RESULTS: The differences in the clinical factors of PTC to FTC were as follows: PTC had a higher incidence (3.9:1); these patients were younger at presentation (median age, 44 vs 49), showed a higher female-male ratio (4.5 vs 2.9) and smaller primary tumor size (median 2 cm vs 3.5 cm), and a higher incidence of multifocal disease (28.3% vs 18.1%), extrathyroidal extension (39.4% vs 14%), and more lymph node metastases (33.3% vs 12.1%). The incidence of distant metastases was higher for patients with FTC (28.8% vs 8.9%), and cause-specific survival rates were lower (p =.001). The locoregional control rates were not significantly different (p =.2). The 10-year cause-specific survival, freedom from distant metastasis, and locoregional failure figures for PTC compared with FTC were 92.1% vs 81%, 90.8% vs 72.3%, and 78.5% vs 83%.
CONCLUSIONS: Although patients with PTC tend to have more advanced locoregional disease compared with those with FTC, the likelihood of locoregional control is similar, and the probability of cure is better. Copyright 2002 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12112541     DOI: 10.1002/hed.10080

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  12 in total

1.  Preoperative dexmedetomidine attenuates hemodynamic responses to hydrodissection in patients undergoing robotic thyroidectomy.

Authors:  Mae-Hwa Kang; Ho-Jin Lee; Young-Jin Lim; Young-Tae Jeon; Jung-Won Hwang; Hee-Pyoung Park
Journal:  J Anesth       Date:  2014-09-28       Impact factor: 2.078

2.  Nodal metastasis in well-differentiated follicular carcinoma of the thyroid: Its incidence and clinical significance.

Authors:  Mitsuyoshi Hirokawa; Yasuhiro Ito; Seiji Kuma; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Akira Miyauchi
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

Review 3.  New developments in the diagnosis and treatment of thyroid cancer.

Authors:  David F Schneider; Herbert Chen
Journal:  CA Cancer J Clin       Date:  2013-06-24       Impact factor: 508.702

Review 4.  Staging systems for papillary thyroid carcinoma: a review and comparison.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo; Wai-Fan Chan; King-Yin Lam; Koon-Yat Wan
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

5.  [Lymphadenectomy for thyroid and lymph node carcinomas].

Authors:  O Gimm; H Dralle
Journal:  Chirurg       Date:  2007-03       Impact factor: 0.955

6.  Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers.

Authors:  Brian Hung-Hin Lang; Sin-Ming Chow; Chung-Yau Lo; Stephen C K Law; King-Yin Lam
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

7.  Neck Ultrasound in Patients with Follicular Thyroid Carcinoma.

Authors:  Konstantinos Segkos; Kyle Porter; Leigha Senter; Matthew D Ringel; Fadi A Nabhan
Journal:  Horm Cancer       Date:  2018-08-07       Impact factor: 3.869

8.  Cause-specific mortality after diagnosis of thyroid cancer: a large population-based study.

Authors:  Binbin Du; Fang Wang; Leiming Wu; Zheng Wang; Dianhong Zhang; Zhen Huang; Lu Gao; Yapeng Li; Cui Liang; Pengcheng Li; Rui Yao
Journal:  Endocrine       Date:  2020-08-08       Impact factor: 3.633

Review 9.  Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.

Authors:  Naoki Fukuda; Shunji Takahashi
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

10.  Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer: a propensity score-matching study.

Authors:  Joonseon Park; Kwangsoon Kim; Dong-Jun Lim; Ja Seong Bae; Jeong Soo Kim
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.